Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2
Journal of Virology · 2025
DOI: 10.1128/jvi.01307-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Hengrui Hu und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan, China. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, Antibodies, Monoclonal, COVID-19 Drug Treatment. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), Hubei National Science Foundation for DIstinguished Young Scholars, Reasearch Project of Key Laboratory of Highly Pathogentic Viruses and Biosafety.
Abstract (Originalsprache)
The emergence of novel variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to pose an ongoing challenge for global public health services, highlighting the urgent need for effective therapeutic interventions. Neutralizing monoclonal antibodies (mAbs) are a major therapeutic strategy for the treatment of COVID-19 and other viral diseases. In this study, we employed hybridoma technology to generate mAbs that target the BA.5 receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Through a comprehensive screening process, we identified four mAbs capable of effectively neutralizing BA.5, XBB.1.16, and related variant infections in vitro , among which ORB10 was found to neutralize BA.5 variants with a plaque reduction neutralization test (PRNT 50 ) of 8.7 ng/mL. Additionally, competitive binding assays, sequencing of heavy and light chain variable regions, and binding kinetics characterization provided insights into the epitopes and binding affinities of the identified mAbs. Moreover, in vivo experiments in the K18-hACE2 mouse model demonstrated the protective efficacy of ORB10 against both BA.5 and XBB.1.16 variants. Finally, cryo-electron microscopy structural analysis of the ORB10–RBD complex identified key residues involved in the antibody–antigen interactions, providing insights into the molecular mechanisms of neutralization and immune escape of SARS-CoV-2 Omicron variants from mAbs. IMPORTANCE The ongoing evolution of SARS-CoV-2 has led to the emergence of variants capable of evading immune responses elicited by natural infection and vaccination, especially the highly transmissible and immune-evasive Omicron variants. This study generated and characterized a panel of monoclonal antibodies (mAbs) specifically targeting the RBD of the Omicron BA.5 variant, of which the ORB10 showed efficacy against Omicron BA.5 and XBB.1.16 variants both in vitro and in vivo . Cryo-EM structural analysis further elucidated the binding epitope interactions and neutralization mechanism between ORB10 and the BA.5 RBD protein. This study enhances our understanding of antibody-mediated neutralization of SARS-CoV-2 and provides valuable insights into the development of effective therapeutic strategies to combat ongoing SARS-CoV-2 variant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan, China.
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China.
- Hubei Jiangxia Laboratory, Wuhan, China.
ORCID-Profile: Hengrui Hu, Chao Leng, Rui Gong, Fei Deng, Zhihong Hu, Sheng Cao, Manli Wang
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- Hubei National Science Foundation for DIstinguished Young Scholars
- Reasearch Project of Key Laboratory of Highly Pathogentic Viruses and Biosafety
Zitieren
APA
Hu, H., Leng, C., Shu, Y., Peng, L., Wu, F., Liu, J., Zhang, X., Zhou, W., Xiao, Q., Li, Y., Wu, B., Shen, J., Li, J., Gong, R., Yan, B., Deng, F., Hu, Z., Cao, S., & Wang, M. (2025). Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2. Journal of Virology. https://doi.org/10.1128/jvi.01307-24
Vancouver
Hu H, Leng C, Shu Y, Peng L, Wu F, Liu J, et al. Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2. Journal of Virology. 2025. doi:10.1128/jvi.01307-24
BibTeX
@article{Hu2025,
author = {Hu, Hengrui and Leng, Chao and Shu, Yanni and Peng, Lu and Wu, Fan and Liu, Jia and Zhang, Xiaolu and Zhou, Wei and Xiao, Qinghong and Li, Yufeng and Wu, Bihao and Shen, Jiamei and Li, Jiang and Gong, Rui and Yan, Bing and Deng, Fei and Hu, Zhihong and Cao, Sheng and Wang, Manli},
title = {Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01307-24}
}
EUVIMED